Security key
829401108
Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share (SION)
CUSIP: 829401108
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Total 13F shares
- 42,840,564
- Total 13F value
- $1,259,943,482
- Share change
- -608,448
- SEC-reported price per share
- $29.41
- Number of holders
- 78
- Value change
- -$14,718,322
- Number of buys
- 38
- Number of sells
- 25
- Shares outstanding
- 45,002,549
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
78
Top holders
10
SION full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Sionna Therapeutics, Inc. SEC filings
Sionna Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 829401108
Recent filing periods:
Ownership snapshot
Top reported holders of SION - Sionna Therapeutics, Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TPG GP A, LLC
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
30 Sep 2025
13F
13D/G
Lead comparable stake: 15%
13D/G row: TPG GP A, LLC
Showing 1-6 of 15 holder rows.
Quick read
TPG GP A, LLC leads the comparable SEC ownership view at 15%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TPG GP A, LLC's linked filing trail.
Comparable ownership
Top 5
TPG GP A, LLC
15%
Enavate Sciences GP, LLC
5.6%
JPMORGAN CHASE & CO
4.4%
RA CAPITAL MANAGEMENT, L.P.
23%
ORBIMED ADVISORS LLC
8.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TPG GP A, LLC |
13F
13D/G
Company
|
15%
from 13D/G
|
$117,025,091
6,744,962 shares
|
— | 30 Jun 2025 |
| Enavate Sciences GP, LLC |
13F
13D/G
Company
|
5.6%
from 13D/G
|
$42,993,821
2,478,030 shares
|
— | 30 Jun 2025 |
| JPMORGAN CHASE & CO |
13D/G
13F
Company
|
4.4%
|
$58,251,993
1,980,626 shares
|
-$7,075,145 | 30 Sep 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
23%
|
$181,226,337
10,445,322 shares
|
— | 30 Jun 2025 |
| ORBIMED ADVISORS LLC |
13F
Company
|
8.2%
|
$64,281,039
3,704,959 shares
|
— | 30 Jun 2025 |
| Atlas Venture Life Science Advisors, LLC |
13F
Company
|
8.2%
|
$64,091,247
3,694,020 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
78
Shares
42,840,564
Rows available
78
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q1 2026 Across Filers
Q1 2026 holders
121
Q3 2025 holders
78
Holder diff
-43
| Investor | Q1 2026 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend